A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models

被引:40
|
作者
Gueorguieva, Luelina
Ogungbenro, Kayode
Graham, Gordon
Glatt, Sophie
Aarons, Leon
机构
[1] Lilly Res Ctr Ltd, Global PK PD, Windlesham GU20 6PH, Surrey, England
[2] Univ Manchester, Sch Pharm & Pharmaceut Sci, Ctr Appl & Pharmacokinet Res, Manchester M13 9PL, Lancs, England
[3] Pfizer Ltd, Sandwich CT13 9NJ, Kent, England
关键词
D-optimal design; multivariate response; pharmacokinetics; pharmacodynamics;
D O I
10.1016/j.cmpb.2007.01.004
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
The design of pharmacokinetic and pharmacodynamic experiments concerns a number of issues, among which are the number of observations and the times when they are taken. often a model is used to describe these data and the pharmacokinetic-pharmacodynamic behavior of a drug. Knowledge of the data analysis model at the design stage is beneficial for collecting patient data for parameter estimation. A number of criteria for model-oriented experiments, which maximize the information content of the data, are available. In this paper we present a program, Popdes, to investigate the D-optimal design of individual and population multivariate response models, such as pharmacokinetic-pharm aco dynamic, physiologically based pharmacokinetic, and parent drug and metabolites models. A pre-clinical and clinical pharmacokinetic-pharmacodynamic model describing the concentration-time profile and effect of an oncology compound in development is used for illustration. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:51 / 61
页数:11
相关论文
共 50 条
  • [1] Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments
    Hooker, A
    Vicini, P
    [J]. AAPS JOURNAL, 2005, 7 (04): : E759 - E785
  • [2] Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments
    Andrew Hooker
    Paolo Vicini
    [J]. The AAPS Journal, 7
  • [3] Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models
    Siripuram, Vijay K.
    Wright, Daniel F. B.
    Barclay, Murray L.
    Duffull, Stephen B.
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 (05) : 415 - 423
  • [4] Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - Dealing with unbalanced designs
    Ogungbenro, Kayode
    Gueorguieva, Ivelina
    Majid, Oneeb
    Graham, Gordon
    Aarons, Leon
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2007, 34 (03) : 313 - 331
  • [5] An Approach for Identifiability of Population Pharmacokinetic-Pharmacodynamic Models
    Shivva, V.
    Korell, J.
    Tucker, I. G.
    Duffull, S. B.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2013, 2 (06):
  • [6] Optimal design for multivariate response pharmacokinetic models
    Gueorguieva, I
    Aarons, L
    Ogungbenro, K
    Jorga, KM
    Rodgers, T
    Rowland, M
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2006, 33 (02) : 97 - 124
  • [7] Optimal Design for Multivariate Response Pharmacokinetic Models
    Ivelina Gueorguieva
    Leon Aarons
    Kayode Ogungbenro
    Karin M. Jorga
    Trudy Rodgers
    Malcolm Rowland
    [J]. Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33
  • [8] Optimal designs for composed models in pharmacokinetic-pharmacodynamic experiments
    Dette, Holger
    Pepelyshev, Andrey
    Wong, Weng Kee
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2012, 39 (03) : 295 - 311
  • [9] Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design
    Merlé, Y
    Tod, M
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (04) : 363 - 388
  • [10] Simultaneous versus sequential optimal design for pharmacokinetic-pharmacodynamic models with FO and FOCE considerations
    J. M. McGree
    J. A. Eccleston
    S. B. Duffull
    [J]. Journal of Pharmacokinetics and Pharmacodynamics, 2009, 36 : 101 - 123